VJVivienne Margaret Jackson

Vivienne Margaret Jackson

*This is an algorithmically generated author record based on publicly available information.

Vivienne Margaret Jackson has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pharmacokinetics and pharmacodynamics of PF‐05190457: The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects

    by William S. Denney, Gabriele E. Sonnenberg, Santos Carvajal‐Gonzalez, Theresa Tuthill, V. Margaret Jackson

    Aim: To evaluate safety, tolerability and pharmacokinetics of oral PF‐05190457, an oral ghrelin receptor inverse agonist, in healthy adults.Methods: Single (SAD) and multiple ascending dose (MAD) studies were randomised, placebo‐controlled, double‐blind studies. Thirty‐five healthy men (age 38.2 ± 10.4 years; body mass index 24.8 ± 3.1 kg m–2 [mean ± standard deviation]) received ≥1 dose (2, 10, 40 [divided], 50, 100, 150, and 300 [single or divided] mg) of PF‐05190457 and/or placebo in the SAD. In the MAD study, 35 healthy men (age 39.7 ± 10.1 years; body mass index 25.9 ± 3.3 kg m–2) received ≥1 dose (2, 10, 40 and 100 mg twice daily) of PF‐05190457 and/or placebo daily for 2 weeks.Results: PF‐05190457 absorption was rapid with a Tmax of 0.5–3 hours and a half‐life between 8.2–9.8 hours. PF‐05190457 dose‐dependently blocked ghrelin (1 pmol kg–1 min–1)‐induced growth hormone (GH) release with (mean [90% confidence interval]) 77% [63–85%] inhibition at 100 mg. PF‐05190457 (150 mg) delayed gastric emptying lag time by 30% [7–58%] and half emptying time by 20% [7–35%] with a corresponding decrease in postprandial glucose by 9 mg dL–1. The most frequent adverse event reported by 30 subjects at doses ≥50 mg was somnolence. PF‐05190457 plasma concentrations also increased heart rate up to 13.4 [4.8–58.2] beats min–1 and, similar to the effect on glucose and ghrelin‐induced GH, was lost within 2 weeks.Conclusions: PF‐05190457 is a well‐tolerated first‐in‐class ghrelin receptor inverse agonist with acceptable pharmacokinetics for oral daily dosing. Blocking ghrelin receptors inhibits ghrelin‐induced GH, and increases heart rate, effects that underwent tachyphylaxis with chronic dosing. PF‐051940457 has the potential to treat centrally‐acting disorders such as insomnia.


  • Open Access

    Pharmacological characterization of the first in class clinical candidate PF‐05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose‐dependent insulin secretionex vivo

    by J Kong, J Chuddy, I A Stock, P M Loria, S V Straub, C Vage, K O Cameron, S K Bhattacharya, K Lapham, K F McClure, et al.

    Background and Purpose: Ghrelin increases growth hormone secretion, gastric acid secretion, gastric motility and hunger but decreases glucose‐dependent insulin secretion and insulin sensitivity in humans. Antagonizing the ghrelin receptor has potential as a therapeutic approach in the treatment of obesity and type 2 diabetes. Therefore, the aim was to pharmacologically characterize the novel small‐molecule antagonist PF‐05190457 and assess translational pharmacologyex vivo.Experimental Approach: Radioligand binding in filter and scintillation proximity assay formats were used to evaluate affinity, and europium‐labelled GTP to assess functional activity. Rat vagal afferent firing and calcium imaging in dispersed islets were used asnativetissues underlying food intake and insulin secretion respectively.Key Results: PF‐05190457 was a potent and selective inverse agonist on constitutively active ghrelin receptors and acted as a competitive antagonist of ghrelin action, with a humanKdof 3 nM requiring 4 h to achieve equilibrium. Potency of PF‐05190457 was similar across different species. PF‐05190457 increased intracellular calcium within dispersed islets and increased vagal afferent firing in a concentration‐dependent manner with similar potency but was threefold less potent as compared with thein vitro Kiin recombinant overexpressing cells. The effect of PF‐05190457 on rodent islets was comparable with glibenclamide, but glucose‐dependent and additive with the insulin secretagogue glucagon‐like peptide‐1.Conclusions and Implications: Together, these data provide the pharmacologicalin vitroandex vivocharacterization of the first ghrelin receptor inverse agonist, which has advanced into clinical trials to evaluate the therapeutic potential of blocking ghrelin receptors in obesity and type 2 diabetes.


  • An ex vivo Multi-Electrode Approach to Evaluate Endogenous Hormones and Receptor Subtype Pharmacology on Evoked and Spontaneous Neuronal Activity within the Ventromedial Hypothalamus; Translation from Female Receptivity

    by Clair Booth, Christopher P. Wayman, Vivienne Margaret Jackson

    The ventromedial hypothalamus (VMH) controls female rodent copulatory behavior, which can be modulated by injection of various compounds into the VMH. Aim. The aim was to determine whether evoked excitatory postsynaptic potentials (EPSPs) or single-unit activity within the VMH ex vivo is a better parameter to predict lordosis. VMH slices were placed onto a 64 microelectrode chip and spontaneous single-unit activity was recorded or slices stimulated to evoke EPSPs. The sodium channel blocker, tetrodotoxin and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate antagonist, 6,7-dinitroquinoxaline-2,3-dione (DNQX) inhibited EPSPs, confirming EPSPs were glutamatergic in origin. The GABA(A) antagonist bicuculline potentiated EPSPs implying endogenous GABA tone. Single-unit activity was abolished by tetrodotoxin but unaffected by DNQX or bicuculline. Glutamatergic neurotransmission was greatest during metestrous and following ovariectomization. The number of regions within the VMH eliciting single-unit activity was reduced following ovariectomy without changing spike frequency. Adrenergic agents increasing lordosis via the VMH in vivo, decreased glutamate neurotransmission but increased single-unit activity. Conversely, agents decreasing lordosis via the VMH increased glutamatergic neurotransmission and inhibited single-unit activity (8-OH-DPAT, [D-Ala(2), N-Me-Phe(4), Gly-ol(5)]-enkephalin, corticotropin releasing factor, bicuculline). Melanocortin and pituitary adenylate cyclase-activating polypeptide agonists had no effect. Here we present a novel, robust VMH in vitro technique that (i) is consistent with the hypothesis that glutamate via non-NMDA receptors inhibits lordosis; (ii) glutamate is under the endogenous tone of GABA and steroid hormones; (iii) inhibition of lordosis during metestrous and following ovariectomy potentiates glutamatergic neurotransmission; (iv) activation of G(q)- and G(i)-coupled receptors decreases and increases glutamate neurotransmission, respectively, with an inverse correlation on single-unit activity; (v) activation of G(s)-coupled receptors has no direct effect on glutamate or single-unit activity; and (vi) potency, receptor subtypes and localization can be determined prior to in vivo studies.


  • Neuropeptide Modulation of a Lumbar Spinal Reflex: Potential Implications for Female Sexual Function

    by Lesley A. Wilson, Chris P. Wayman, V. Margaret Jackson

    Introduction: Neuropeptides are known to modulate female receptivity. However, even though receptivity is a spinal reflex, the role of neuropeptides within the spinal cord remains to be elucidated.Aim: The aims were to (i) investigate neuropeptides in the lumbosacral region; and (ii) determine how neuropeptides modulate glutamate release from stretch Ia fibers, touch sensation Aβ fibers and Aδ/C pain fibers.Main Outcome Measures: Neuropeptide modulation of the lumbosacral dorsal-root ventral-root reflex in vitro.Methods: Spinal cords were removed from Sprague-Dawley rats in compliance with UK Home Office guidelines. Hemisected cords were superfused with aCSF and the dorsal root (L4–S1) was stimulated to evoke glutamate release. A biphasic reflex response was evoked from the opposite ventral root consisting of a monosynaptic (Ia fibers) and polysynaptic (Aβ, Aδ/C fibers) component.Results: The µ opioid receptor (MOR) agonist DAMGO inhibited the monosynaptic (EC50 0.02 ± 0.02 nM) and polysynaptic area (EC50 125 ± 167 nM) but not polysynaptic amplitude. Oxytocin and corticotrophin releasing factor (CRF) inhibited the monosynaptic amplitude (EC50, 1.4 ± 1.0 nM and EC50 4.3 ± 3.5 nM, respectively), polysynaptic amplitude (EC50 18.2 ± 28.0 nM and EC50, 9.5 ± 13.3 nM, respectively), and area (EC50 11.6 ± 13.0 nM and EC50, 2.8 ± 3.3 nM, respectively); effects that were abolished by oxytocin and CRF1 antagonists, L-368899 and 8w. Melanocortin agonists solely inhibited the monosynaptic component, which were blocked by the MC3/4 receptor antagonist SHU9119.Conclusion: These data suggest endogenous neuropeptides are released within the lumbosacral spinal cord. Melanocortin agonists, oxytocin, CRF, and DAMGO via MC4, oxytocin, CRF1, and MOR inhibit glutamate release but with differing effects on afferent fiber subtypes. Melanocortins, oxytocin, CRF, and DAMGO have the ability to modulate orgasm whereas oxytocin, CRF and DAMGO can increase pain threshold. Oxytocin and CRF may dampen touch sensation.


  • Pharmacological profiling of neuropeptides on rabbit vaginal wall and vaginal artery smooth muscle in vitro

    by K L Aughton, K Hamilton-Smith, J Gupta, J S Morton, C P Wayman, V M Jackson

    Hypothalamic neuropeptides centrally modulate sexual arousal. However, the role of neuropeptides in peripheral arousal has been ignored. Vascular and non-vascular smooth muscle relaxation in the vagina is important for female sexual arousal. To date, in vitro studies have focused on vaginal strips with no studies on vaginal arteries. The aim of this study was to compare the effects of sexual hypothalamic neuropeptides on rabbit vaginal wall strips and arteries. Tissue bath and wire myography techniques were used to measure isometric tension from strips and arteries, respectively. Pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) relaxed both preparations, effects that were only antagonized by the VIP/PACAP antagonist VIP6-28 (10 nM) and the PAC(1) antagonist PACAP 6-38 (1 microM). The melanocortin agonist alpha-melanocortin-stimulating hormone (1 microM), but not bremelanotide (1 microM), also relaxed both preparations. Oxytocin and vasopressin contracted vaginal preparations, which could be antagonized by the V(1A) antagonist SR 49059. Neuropeptide Y (NPY) and the NPY Y(1) agonist Leu(31), Pro(34) NPY only contracted arteries, which was antagonized by the NPY Y(1) receptor antagonist BIBP 3226. Melanin-concentrating hormone (MCH; 1 microM) contracted arteries. Hypothalamic neuropeptides can exert contractile and relaxant effects on vaginal strips and arteries. NPY Y(1), V(1A), MCH(1) antagonists as well as VIP/PAC(1) agonists may have therapeutic potential in both central and peripheral female sexual arousal. Differences in effect of neuropeptides between preparations raise the question of which preparation is important for female sexual arousal.


  • Oxytocin‐induced contractions within rat and rabbit ejaculatory tissues are mediated by vasopressin V1Areceptors and not oxytocin receptors

    by J Gupta, R J Russell, C P Wayman, D Hurley, V M Jackson

    Background and purpose: Oxytocin is believed to be involved in ejaculation by increasing sperm number and contracting ejaculatory tissues. However, oxytocin may mediate these effects via oxytocin or vasopressin (AVP) receptors. The aim of this study was to determine the effect of oxytocin and AVP on peripheral tissues involved in ejaculation and to identify the receptor subtype(s) involved.Experimental approach: Standard tissue bath techniques were used to measure isometric tension from tissues involved in ejaculation and erection.Key results: Oxytocin and AVP failed to elicit a tonic contractile response in rat and rabbit testes, vas deferens, epididymis, seminal vesicles and prostate. In contrast, oxytocin and AVP elicited large tonic contractions in erectile (corpus spongiosum and corpus cavernosum) and ejaculatory (prostatic urethra, bladder neck and ejaculatory duct) tissues in a concentration‐dependent manner. The selective oxytocin agonist, [Thr4,Gly7]‐oxytocin and the V2agonist, [deamino‐Cys1,Val4,D‐Arg8]‐vasopressin (dDAVP), failed to contract tissues. Oxytocin and AVP‐induced contractions were weakly antagonized by the selective oxytocin antagonist, L‐368899 but potently antagonized by the V1Aantagonist, SR49059. The V1Bantagonist SSR149415 failed to antagonize AVP contractions except in rabbit bladder neck. Neither L‐368899 nor SR49059 antagonized endothelin‐1‐induced contractions.Conclusions and implications: The contractile effect of oxytocin on rat and rabbit ejaculatory and erectile tissues is mediated via V1Areceptors. Endothelin‐1‐induced contractions are not due to endogenous oxytocin or AVP release. V1Areceptor antagonists may have a therapeutic role in both erectile dysfunction and premature ejaculation.British Journal of Pharmacology(2008)155, 118–126; doi:10.1038/bjp.2008.226; published online 16 June 2008